Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
- Details
- Category: Novartis
Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g(1). Fabhalta specifically targets the alternative complement pathway of the immune system.
Vividion Therapeutics to expand with new global research and development center
- Details
- Category: Bayer
Vividion Therapeutics, Inc. (Vividion), a clinical stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer AG.
Pfizer announces positive topline results From Phase 3 study of hemophilia A gene therapy candidate
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A.
The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment.
Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Details
- Category: Bayer
The Phase III ARANOTE trial, investigating darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of rPFS. Darolutamide plus ADT significantly increased rPFS compared to placebo plus ADT. The safety data were comparable between both treatment arms and reconfirm the established tolerability profile of darolutamide in advanced prostate cancer.
Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies.
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
- Details
- Category: Bayer
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track Designation for AB-1005, which is being developed for moderate Parkinson's disease. AB-1005 has also been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA) innovative medicine designation, for the treatment of Parkinson's disease.
GSK and CureVac to restructure collaboration into new licensing agreement
- Details
- Category: GlaxoSmithKline
GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq: CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritise investment and focus their respective mRNA development activities.
Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases.
More Pharma News ...
- Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
- Berlin Center for Gene and Cell Therapies kicked off in Berlin
- Bayer receives Breakthrough Therapy designation in China for BAY 2927088
- GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies
- Pfizer's LORBRENA® CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression
- BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease cell therapy candidate bemdaneprocel
- Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration